Pfizer Global Research and Development, 445 Eastern Point Road, Groton, CT 06340, United States.
Bioorg Med Chem Lett. 2011 Oct 1;21(19):5957-60. doi: 10.1016/j.bmcl.2011.07.061. Epub 2011 Jul 27.
On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a series of related pyrrolidin-3-yl-N-methylbenzamides were synthesized and evaluated as H(3) receptor antagonists. In particular, compound 32 exhibits potent H(3) receptor binding affinity, improved pharmaceutical properties and a favorable in vivo profile.
在之前报道的苯并咪唑 1,3'-联吡咯烷苯甲酰胺(1)的基础上,我们合成了一系列相关的吡咯烷-3-基-N-甲基苯甲酰胺,并将其作为 H(3)受体拮抗剂进行了评估。特别是化合物 32 表现出很强的 H(3)受体结合亲和力、改善的药物性质和良好的体内特性。